PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ARCA biopharma, Inc. (ABIO)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00211Y5069
CUSIP00211Y506
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$24.58M
EPS-$0.37
EBITDA (TTM)-$7.12M
Year Range$1.56 - $2.16
Target Price$7.00
Short %1.76%
Short Ratio7.37

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ABIO

ARCA biopharma, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in ARCA biopharma, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%0.00%100.00%200.00%300.00%400.00%500.00%OctoberNovemberDecember2024FebruaryMarch
-100.00%
451.60%
ABIO (ARCA biopharma, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

ARCA biopharma, Inc. had a return of 1.18% year-to-date (YTD) and -19.63% in the last 12 months. Over the past 10 years, ARCA biopharma, Inc. had an annualized return of -39.43%, while the S&P 500 had an annualized return of 10.71%, indicating that ARCA biopharma, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date1.18%7.96%
1 month2.99%2.87%
6 months-16.50%15.63%
1 year-19.63%31.48%
5 years (annualized)-25.68%12.80%
10 years (annualized)-39.43%10.71%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-6.47%3.77%
20230.49%-1.95%-10.95%1.68%-6.59%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for ARCA biopharma, Inc. (ABIO) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ABIO
ARCA biopharma, Inc.
-0.85
^GSPC
S&P 500
2.54

Sharpe Ratio

The current ARCA biopharma, Inc. Sharpe ratio is -0.85. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-2.00-1.000.001.002.003.00OctoberNovemberDecember2024FebruaryMarch
-0.85
2.54
ABIO (ARCA biopharma, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


ARCA biopharma, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-100.00%
-0.50%
ABIO (ARCA biopharma, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the ARCA biopharma, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ARCA biopharma, Inc. was 100.00%, occurring on Feb 1, 2024. The portfolio has not yet recovered.

The current ARCA biopharma, Inc. drawdown is 100.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Nov 16, 20005837Feb 1, 2024
-87.35%Sep 29, 1997385Apr 9, 1999190Jan 7, 2000575
-14.06%Aug 12, 19976Aug 19, 199714Sep 9, 199720
-7.58%May 26, 20001May 26, 20001May 30, 20002
-4.74%Apr 17, 20001Apr 17, 20001Apr 18, 20002

Volatility

Volatility Chart

The current ARCA biopharma, Inc. volatility is 5.50%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%OctoberNovemberDecember2024FebruaryMarch
5.50%
3.37%
ABIO (ARCA biopharma, Inc.)
Benchmark (^GSPC)

Financials

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM2023202220212020
Revenue

Total Revenue

0.000.000.000.000.00

Cost Of Revenue

111.00K111.00K114.00K91.00K93.00K

Gross Profit

-111.00K-111.00K-114.00K-91.00K-93.00K
Operating Expenses

Selling, General & Admin Expenses

6.28M6.28M5.85M5.50M4.77M

R&D Expenses

1.01M1.01M4.75M13.83M4.99M

Total Operating Expenses

7.30M7.30M10.60M19.34M9.77M
Income

Income Before Tax

-5.34M-5.34M-9.93M-19.32M-9.75M

Operating Income

-7.30M-7.30M-10.60M-19.34M-9.77M

EBIT

-7.36M-7.30M-10.60M-19.34M-9.77M

Earnings From Continuing Operations

-5.34M-5.42M-9.93M-19.32M-9.74M

Net Income

-4.37M-5.34M-9.26M-19.23M-9.74M

Income Tax Expense

-1.00M-111.00K-670.00K-91.00K-9.00K

Interest Expense

-450.00K0.00675.00K13.00K9.00K

Other Non-Operating Income (Expenses)

1.96M1.96M670.00K13.00K19.00K

Extraordinary Items

0.000.000.000.000.00

Discontinued Operations

0.000.000.000.000.00

Effect Of Accounting Charges

0.000.000.000.000.00

Non Recurring

0.000.000.000.000.00

Minority Interest

0.000.000.000.000.00

Other Items

0.000.000.000.000.00
Values in USD except per share items